This trial is active, not recruiting.

Condition cosmetic surgery
Treatments mist therapy, standard postoperative incision care
Phase phase 4
Sponsor Celleration, Inc.
Start date October 2010
End date April 2013
Trial size 40 participants
Trial identifier NCT01206855, Celleration-NU-01


A clinical trial to evaluate the effect of MIST Therapy on outcomes after cosmetic procedures(including facelifts, blepharoplasties, breast augmentations and reductions, mastopexies, and abdominoplasties) traditionally associated with pain, swelling, bruising, and scarring. The study will test the hypothesis that MIST Therapy can decrease the incidence and severity of these surgical sequelae throughout the acute and sub-acute phases of healing.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (investigator)
Primary purpose treatment
(Active Comparator)
One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
standard postoperative incision care
Incision cleansing, topical creams, and dressing as needed
(Active Comparator)
One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
mist therapy MIST device
Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.

Primary Outcomes

Reduction in swelling, bruising, firmness and pain
time frame: 2-6 weeks
Reduction in wound healing complications
time frame: 12 weeks
Improvements in scarring
time frame: 12 weeks

Secondary Outcomes

Patient satisfaction
time frame: 12 weeks

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Subject must be between 18-75 years of age - Subject must be compliant with the study visits - Subject must be in good health - Subject must be able to provide written informed consent - Subject must be undergoing one or more of the following bilateral procedures: - Rhytidectomies - Blepharoplasty - Breast augmentation - Mastopexy - Breast reduction - Abdominoplasty Exclusion Criteria: - Subject has any medical condition that would result in poor wound healing - Subject has any medical condition that would result in poor scarring - Subject is taking medications that may affect healing or scarring, including Arnica - Subject has diabetes - Area to be treated has been irradiated - Subject is undergoing a secondary procedure that may be associated with prior scar tissue in the area undergoing surgery - Subject has any medical condition that in the opinion of the Investigator would make the subject an inappropriate candidate for this study, including a higher than usual concern for surgical complications - Subject has electronic implants or prosthesis - Subject has cardiac pacemaker - Pregnant woman - Skin cancer

Additional Information

Official title Use of MIST Ultrasound Therapy to Minimize Edema, Bruising and Scarring After Cosmetic Surgery Procedures of the Face and Body
Principal investigator Robert D Galiano, MD
Description A post-market, single-center, prospective, randomized, single-blinded study. Each subject serves as her/his own control. The procedures chosen are bilateral, and each subject will have one side of the surgical site treated with MIST Therapy and the other side left untreated except for the surgeon's usual postoperative care protocol. Study objectives: Comparison between MIST-treated side versus the contralateral untreated side on the reduction in swelling, bruising, firmness, pain, and wound healing complications; the potential improvements in scarring; and the improvements in patient satisfaction. Subject recruitment: A total of 30 subjects will be enrolled into the study. The MIST-treated side will be randomly assigned. The assigned MIST-treated side will be known to the subject and assistant providing MIST Therapy, but will not be known to the Investigator/assessor. Protocol and procedures: Subjects will be followed until 12 weeks post-surgery. The side assigned for MIST Therapy treatment will be treated weekly, beginning 2-3 days post-surgery, and continuing until 3 weeks post-surgery. A baseline evaluation will include demographic data, medical and surgical history, smoking history, laboratory tests, and digital photography of each side of the wound. Subjects will be assessed at the following timepoints post-surgery: Days 2,7,14, 21, 28, 42 and 84. The following procedures and assessments will be obtained at specific timepoints: - MIST Therapy treatments to the assigned wound side (Days 2, 7, 14, 21) - Digital photographs (Baseline, Days 14, 21, 42, 84) - Bruising assessment (Days 7 and 14) - Pain assessment (Days 7 and 14) - Swelling assessment (Days 7 and 14) - Firmness assessment (Days 21 and 42) - Scar assessment (Days 21 and 84) - Subject satisfaction (Day 84) - Concomitant treatments including use of moisturizers, scar creams and compression garments(all timepoints) - Wound healing complication assessment (all timepoints) - Adverse event assessment (all timepoints following informed consent)
Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by Celleration, Inc..